Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05583734 · ClinicalTrials.gov registry record · NA

A Prospective Study of Conventional Bone Marrow Biopsy Versus Portomar(TM) Biopsy

A NA study of Hematologic Malignancy, sponsored by Aperture Medical Technology.

Recruiting
Registry status
NA
Development phase
32
Enrollment target
1
Study location

NCT05583734: Recruiting NA study of Hematologic Malignancy, sponsored by Aperture Medical Technology.

NCT05583734 is a NA study of Hematologic Malignancy that is actively recruiting participants, run by Aperture Medical Technology. The registered enrollment target is 32 participants, below the 228-participant average among 48 other Hematologic Malignancy trials with a reported enrollment target (86% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05583734, a NA study of Hematologic Malignancy, is actively recruiting participants, sponsored by Aperture Medical Technology.

RECRUITING
Registry status
NA
Development phase
32 participants
Enrollment target
1
Study location

Study Summary

This is a self-controlled, prospective trial. The objective of this trial is to evaluate the efficacy and safety of the Portomar(TM) device for bone marrow biopsy.

Conditions Studied

Interventions

  • DEVICE Portomar(TM) Device

Study Locations (1)

Texas

  • MD Anderson - Houston

Trial Details

FieldValue
Enrollment Target 32 participants
Start Date 2022-11-22
Est. Completion 2025-10
Phase NA
Aperture Medical Technology

1 total trials

What NCT05583734 shows while recruiting

NCT05583734 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 32 participants, a relatively small participant target, below the 228-participant average among 48 other Hematologic Malignancy trials with a reported enrollment target (86% lower).

The record links to 1 condition, with Hematologic Malignancy appearing as the primary indexed condition, and to 1 intervention - of which Portomar(TM) Device is the first listed.

NCT05583734 reports a single indexed study location in Texas.

Frequently Asked Questions

What is clinical trial NCT05583734 about?

NCT05583734 is a clinical study titled "A Prospective Study of Conventional Bone Marrow Biopsy Versus Portomar(TM) Biopsy". This is a self-controlled, prospective trial. The objective of this trial is to evaluate the efficacy and safety of the Portomar(TM) device for bone marrow biopsy.

What is the current status of trial NCT05583734?

This trial is currently recruiting. It is a NA study. The enrollment target is 32 participants. The study started on 2022-11-22. Estimated completion is 2025-10.

What conditions does trial NCT05583734 study?

This clinical trial studies the following conditions: Hematologic Malignancy.

What interventions are being tested in trial NCT05583734?

The interventions under investigation include: Portomar(TM) Device (DEVICE).

Who is sponsoring clinical trial NCT05583734?

This trial is sponsored by Aperture Medical Technology, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05583734 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Hematologic Malignancy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05583734's enrollment target sits among peer trials

32 33rd of 48 higher than 16 of 48 other Hematologic Malignancy trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Hematologic Malignancy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02445781 · 32 participants · Early Phase 1

    Differing Levels of Hypoglycemia

  • NCT02792270 · 32 participants · NA

    Caloric Restriction In Sarcoma Patients Treated With Pre-Operative RT

  • NCT03068910 · 32 participants · Early Phase 1

    Hyperandrogenemia and Altered Day-night LH Pulse Patterns

  • NCT03208868 · 32 participants · NA

    Leucine Enriched Essential Amino Acid Mixture to Reverse Muscle Loss in Cirrhosis

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05583734, the US trial registry maintained by the National Library of Medicine. NCT05583734 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.